<rss version="2.0"><channel><title>Yahoo! Finance: TR.TO News</title><copyright>Copyright (c) 2016 Yahoo! Inc. All rights reserved.</copyright><link>http://finance.yahoo.com/q/h?s=tr.to</link><description>Latest Financial News for TRILLIUM THERAPEUTICS INC</description><language>en-US</language><lastBuildDate>Mon, 05 Dec 2016 16:40:21 GMT</lastBuildDate><image><url>http://l.yimg.com/a/i/brand/purplelogo/uh/us/fin.gif</url><title>Yahoo! Finance: TR.TO News</title><link>http://finance.yahoo.com/q/h?s=tr.to</link><width>144</width><height>45</height></image><item><title>Trillium Therapeutics, Inc. :TR-CA: Earnings Analysis: Q3, 2016 By the Numbers : December 5, 2016</title><link>http://us.rd.yahoo.com/finance/external/xcapitalcube/rss/SIG=145u9bj26/*http://www.capitalcube.com/blog/index.php/trillium-therapeutics-inc-tr-ca-earnings-analysis-q3-2016-by-the-numbers-december-5-2016/</link><description /><guid isPermaLink="false">yahoo_finance/3033774268</guid><pubDate>Mon, 05 Dec 2016 16:40:21 GMT</pubDate></item><item><title>Trillium Presents Initial Data From Ongoing Study of TTI-621 in Patients With Advanced Hematologic Malignancies at the American Society of Hematology Annual Meeting</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-presents-initial-data-ongoing-170000629.html</link><description>[Marketwired] - Trillium Therapeutics Inc. , a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, today presented data from an ongoing study with its lead drug candidate, ...</description><guid isPermaLink="false">yahoo_finance/957973941</guid><pubDate>Sat, 03 Dec 2016 17:00:00 GMT</pubDate></item><item><title>Trillium Therapeutics Announces Conference Call and Webcast on December 5th to Discuss TTI-621 Data Presented at ASH</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-therapeutics-announces-conference-call-120000220.html</link><description>[Marketwired] - Trillium Therapeutics Inc. , a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it will host a conference call and webcast at 8:30 ...</description><guid isPermaLink="false">yahoo_finance/3181295095</guid><pubDate>Tue, 29 Nov 2016 12:00:00 GMT</pubDate></item><item><title>Trillium reports 3Q loss</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://sg.finance.yahoo.com/news/trillium-reports-3q-loss-140733794.html</link><description /><guid isPermaLink="false">yahoo_finance/3168224048</guid><pubDate>Thu, 10 Nov 2016 14:07:33 GMT</pubDate></item><item><title>Trillium reports 3Q loss</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-reports-3q-loss-140733705.html</link><description /><guid isPermaLink="false">yahoo_finance/686673768</guid><pubDate>Thu, 10 Nov 2016 14:07:33 GMT</pubDate></item><item><title>Trillium Reports Third Quarter 2016 Financial Results and Provides Corporate Update</title><link>http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=128l9mrkd/*http://www.publicnow.com/view/635DD8C8783D892E9BA0FC1B12F829400CAFBB3E</link><description>[at noodls] - Additional clinical data from TTI-621 Phase 1a trial to be presented at 2016 American Society of Hematology (ASH) annual meeting in December Phase 1 trial with TTI-621 in solid tumors open for enrollment ...</description><guid isPermaLink="false">yahoo_finance/2297516602</guid><pubDate>Thu, 10 Nov 2016 12:11:07 GMT</pubDate></item><item><title>Trillium Reports Third Quarter 2016 Financial Results and Provides Corporate Update</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-reports-third-quarter-2016-120000787.html</link><description>[Marketwired] - Trillium Therapeutics Inc. (TRIL)(TR.TO), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today provided a corporate update and reported financial results for the three and nine months ended September 30, 2016. "We established a well-tolerated dose of TTI-621 in first part of the Phase 1a/1b trial in relapsed or refractory hematologic malignancies and look forward to presenting data at next month's ASH meeting. In November, the Phase 1b dose expansion cohorts in the TTI-621 trial in patients with advanced hematologic malignancies were opened for enrollment.</description><guid isPermaLink="false">yahoo_finance/2833267355</guid><pubDate>Thu, 10 Nov 2016 12:00:00 GMT</pubDate></item><item><title>Trillium Therapeutics Announces Investor and Scientific Presentation Schedule for Remainder of 2016</title><link>http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=128s4g59i/*http://www.publicnow.com/view/600F367593083605BAA7341EA88BC10CE5404AF0</link><description>[at noodls] - TORONTO, Nov. 3, 2016 - Trillium Therapeutics Inc. (NASDAQ: TRIL; TSX: TR), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, is scheduled to present ...</description><guid isPermaLink="false">yahoo_finance/2405892859</guid><pubDate>Thu, 03 Nov 2016 11:07:26 GMT</pubDate></item><item><title>Trillium Therapeutics Announces Investor and Scientific Presentation Schedule for Remainder of 2016</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-therapeutics-announces-investor-scientific-110000505.html</link><description>[Marketwired] - Trillium Therapeutics Inc. , a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, is scheduled to present an update on the company's programs and progress ...</description><guid isPermaLink="false">yahoo_finance/3480191075</guid><pubDate>Thu, 03 Nov 2016 11:00:00 GMT</pubDate></item><item><title>Trillium Therapeutics Advances TTI-621 Into Phase 1B Cohort Expansion Enrollment</title><link>http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=128gj51k2/*http://www.publicnow.com/view/A170FD1E9DB7080A80836BDB50FB07DC575F5F3E</link><description>[at noodls] - TORONTO, Nov. 2, 2016 - Trillium Therapeutics Inc. (NASDAQ: TRIL; TSX: TR), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, has advanced its novel ...</description><guid isPermaLink="false">yahoo_finance/3848807346</guid><pubDate>Wed, 02 Nov 2016 11:10:10 GMT</pubDate></item><item><title>Trillium Therapeutics Advances TTI-621 Into Phase 1b Cohort Expansion Enrollment</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-therapeutics-advances-tti-621-110000882.html</link><description>[Marketwired] - Trillium Therapeutics Inc. , a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, has advanced its novel investigational drug TTI-621, a SIRPa-IgG1 Fc fusion ...</description><guid isPermaLink="false">yahoo_finance/1332910865</guid><pubDate>Wed, 02 Nov 2016 11:00:00 GMT</pubDate></item><item><title>Trillium Therapeutics, Inc. :TR-CA: Earnings Analysis: Q2, 2016 By the Numbers : September 16, 2016</title><link>http://us.rd.yahoo.com/finance/external/xcapitalcube/rss/SIG=147ose7u7/*http://www.capitalcube.com/blog/index.php/trillium-therapeutics-inc-tr-ca-earnings-analysis-q2-2016-by-the-numbers-september-16-2016/</link><description /><guid isPermaLink="false">yahoo_finance/1409634109</guid><pubDate>Fri, 16 Sep 2016 16:41:44 GMT</pubDate></item><item><title>Trillium Therapeutics Introduces Industry Postdoctoral Fellowship Program</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-therapeutics-introduces-industry-postdoctoral-110000999.html</link><description>[Marketwired] - Trillium Therapeutics Inc. , a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the company has established an industry postdoctoral ...</description><guid isPermaLink="false">yahoo_finance/3273511851</guid><pubDate>Wed, 31 Aug 2016 11:00:00 GMT</pubDate></item><item><title>Trillium Therapeutics Introduces Industry Postdoctoral Fellowship Program</title><link>http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=1283bon7s/*http://www.publicnow.com/view/0CDDBDB90A821A609779D3C871295010A163F26A</link><description>[at noodls] - Toronto, Ontario, August 31, 2016 - Trillium Therapeutics Inc. (NASDAQ: TRIL; TSX: TR), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today ...</description><guid isPermaLink="false">yahoo_finance/4247710028</guid><pubDate>Tue, 30 Aug 2016 19:53:02 GMT</pubDate></item><item><title>Trillium Therapeutics to Present at Investor and Scientific Conferences in September</title><link>http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=128krum2b/*http://www.publicnow.com/view/CE83C1926A8073643E0B662295F811F5C5EF48F1</link><description>[at noodls] - Toronto, Ontario, August 23, 2016 - Trillium Therapeutics Inc. (NASDAQ: TRIL; TSX: TR), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today ...</description><guid isPermaLink="false">yahoo_finance/2534487299</guid><pubDate>Tue, 23 Aug 2016 11:18:06 GMT</pubDate></item><item><title>Trillium Therapeutics to Present at Investor and Scientific Conferences in September</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-therapeutics-present-investor-scientific-110000254.html</link><description>[Marketwired] - Trillium Therapeutics Inc. , a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the company is scheduled to present an update on ...</description><guid isPermaLink="false">yahoo_finance/2195596355</guid><pubDate>Tue, 23 Aug 2016 11:00:00 GMT</pubDate></item><item><title>Trillium Therapeutics Receives FDA Clearance to Proceed with TTI-621 in Clinical Trial Targeting Solid Tumors and Mycosis Fungoides</title><link>http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=1283rpj20/*http://www.publicnow.com/view/578E365BE972DF950BC4353E7BBB210A4BB433E0</link><description>[at noodls] - Toronto, Ontario, August 17, 2016 - Trillium Therapeutics Inc. (NASDAQ: TRIL; TSX: TR), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today ...</description><guid isPermaLink="false">yahoo_finance/3211463728</guid><pubDate>Wed, 17 Aug 2016 11:11:05 GMT</pubDate></item><item><title>Trillium Therapeutics Receives FDA Clearance to Proceed With TTI-621 in Clinical Trial Targeting Solid Tumors and Mycosis Fungoides</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-therapeutics-receives-fda-clearance-110000353.html</link><description>[Marketwired] - Trillium Therapeutics Inc. , a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the US Food and Drug Administration has provided ...</description><guid isPermaLink="false">yahoo_finance/1148880496</guid><pubDate>Wed, 17 Aug 2016 11:00:00 GMT</pubDate></item><item><title>Trillium reports 2Q loss</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://sg.finance.yahoo.com/news/trillium-reports-2q-loss-115033085.html</link><description /><guid isPermaLink="false">yahoo_finance/2964886933</guid><pubDate>Fri, 12 Aug 2016 11:50:33 GMT</pubDate></item><item><title>Trillium reports 2Q loss</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-reports-2q-loss-115033896.html</link><description /><guid isPermaLink="false">yahoo_finance/1152651927</guid><pubDate>Fri, 12 Aug 2016 11:50:33 GMT</pubDate></item><item><title>Trillium Reports Second Quarter 2016 Financial Results</title><link>http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=128urar7h/*http://www.publicnow.com/view/5840C4FD65ED74FF2FFC47ECC11CB6CF81C674F3</link><description>[at noodls] - On track to report clinical data from TTI-621 program at the end of 2016 IND submitted to initiate a Phase 1 trial with TTI-621 in solid tumors Cash amounted to $60.1 million (CDN) as of June 30, 2016 ...</description><guid isPermaLink="false">yahoo_finance/1816664069</guid><pubDate>Fri, 12 Aug 2016 11:21:04 GMT</pubDate></item><item><title>Trillium Reports Second Quarter 2016 Financial Results</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-reports-second-quarter-2016-110000958.html</link><description>[Marketwired] - Trillium Therapeutics Inc. , a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today provided a corporate update and reported financial results for the ...</description><guid isPermaLink="false">yahoo_finance/1347405217</guid><pubDate>Fri, 12 Aug 2016 11:00:00 GMT</pubDate></item><item><title>Trillium Therapeutics Announces Presentation on TTI-621 Immune Checkpoint Inhibitor Targeting CD47 at European Hematology Association 21st Annual Congress</title><link>http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=128827j93/*http://www.publicnow.com/view/A01EAC28CC44842C0C6024D9A0FBAB6E2BF8FBE9</link><description>[at noodls] - Toronto, Ontario, June 7, 2016 - Trillium Therapeutics Inc. (NASDAQ: TRIL; TSX: TR), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, will present its ...</description><guid isPermaLink="false">yahoo_finance/2381990304</guid><pubDate>Tue, 07 Jun 2016 11:18:07 GMT</pubDate></item><item><title>Trillium Therapeutics Announces Presentation on TTI-621 Immune Checkpoint Inhibitor Targeting CD47 at European Hematology Association 21st Annual Congress</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-therapeutics-announces-presentation-tti-110000757.html</link><description>[Marketwired] - Trillium Therapeutics Inc. , a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, will present its TTI-621 immune checkpoint inhibitor program at the European ...</description><guid isPermaLink="false">yahoo_finance/1446724680</guid><pubDate>Tue, 07 Jun 2016 11:00:00 GMT</pubDate></item><item><title>Trillium Announces Voting Results from The Annual And Special Meeting Of Shareholders</title><link>http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=128fevj1a/*http://www.publicnow.com/view/4DDC0C4FC77155DAE688412638FD438907843A28</link><description>[at noodls] - Toronto, Ontario, May 31, 2016 - Trillium Therapeutics Inc. (NASDAQ:TRIL; TSX: TR) a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced ...</description><guid isPermaLink="false">yahoo_finance/2213852964</guid><pubDate>Tue, 31 May 2016 11:12:10 GMT</pubDate></item><item><title>Trillium Announces Voting Results From the Annual and Special Meeting of Shareholders</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-announces-voting-results-annual-110000934.html</link><description>[Marketwired] - Trillium Therapeutics Inc. , a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the voting results from its Annual and Special Meeting ...</description><guid isPermaLink="false">yahoo_finance/3110641129</guid><pubDate>Tue, 31 May 2016 11:00:00 GMT</pubDate></item><item><title>Trillium Therapeutics Announces Presentation On TTI-621 Immune Checkpoint Inhibitor Targeting CD47 At 2016 ASCO Annual Meeting</title><link>http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=12832p9av/*http://www.publicnow.com/view/351B7C22F590A369AD34C287273958471E5E47D8</link><description>[at noodls] - Toronto, Ontario, May 18, 2016 - Trillium Therapeutics Inc. (NASDAQ:TRIL; TSX: TR) a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, will present its ...</description><guid isPermaLink="false">yahoo_finance/1096564209</guid><pubDate>Wed, 18 May 2016 22:12:04 GMT</pubDate></item><item><title>Trillium Therapeutics Announces Presentation on TTI-621 Immune Checkpoint Inhibitor Targeting CD47 at 2016 ASCO Annual Meeting</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-therapeutics-announces-presentation-tti-210000544.html</link><description>[Marketwired] - Trillium Therapeutics Inc. , a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, will present its TTI-621 immune checkpoint inhibitor program at the Trials ...</description><guid isPermaLink="false">yahoo_finance/3405041823</guid><pubDate>Wed, 18 May 2016 21:00:00 GMT</pubDate></item><item><title>Trillium Reports First Quarter 2016 Financial Results</title><link>http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=128h59ckc/*http://www.publicnow.com/view/55F6B103E54190A40441CD023BA0360152B673B5</link><description>[at noodls] - TTI-621 Phase I clinical trial progressing according to plans Completed acquisition and integration of Fluorinov Cash amounted to $65.8 million as of March 31, 2016 Toronto, Ontario, May 13, 2016 - Trillium ...</description><guid isPermaLink="false">yahoo_finance/1153598000</guid><pubDate>Fri, 13 May 2016 11:28:09 GMT</pubDate></item><item><title>Trillium reports 1Q loss</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://sg.finance.yahoo.com/news/trillium-reports-1q-loss-112732301.html</link><description /><guid isPermaLink="false">yahoo_finance/1742640402</guid><pubDate>Fri, 13 May 2016 11:27:32 GMT</pubDate></item><item><title>Trillium reports 1Q loss</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-reports-1q-loss-112732622.html</link><description /><guid isPermaLink="false">yahoo_finance/111989000</guid><pubDate>Fri, 13 May 2016 11:27:32 GMT</pubDate></item><item><title>Trillium Reports First Quarter 2016 Financial Results</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-reports-first-quarter-2016-110000178.html</link><description>[Marketwired] - Trillium Therapeutics Inc. , a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today provided a corporate update and reported financial results for the ...</description><guid isPermaLink="false">yahoo_finance/980204997</guid><pubDate>Fri, 13 May 2016 11:00:00 GMT</pubDate></item><item><title>Trillium To Provide Update On CD47 Program At The 2016 American Association For Cancer Research Annual Meeting</title><link>http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=128nbtghr/*http://www.publicnow.com/view/2E2343438495F0E5894C3E8CACC13D20A044FBFC</link><description>[at noodls] - Toronto, Ontario - April 14, 2016 - Trillium Therapeutics Inc. (NASDAQ:TRIL; TSX: TR) an immuno-oncology company developing innovative therapies for the treatment of cancer, today announced it will be ...</description><guid isPermaLink="false">yahoo_finance/3282638283</guid><pubDate>Thu, 14 Apr 2016 11:17:09 GMT</pubDate></item><item><title>Trillium to Provide Update on CD47 Program at the 2016 American Association for Cancer Research Annual Meeting</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-cd47-program-2016-american-110000849.html</link><description>[Marketwired] - Trillium Therapeutics Inc. an immuno-oncology company developing innovative therapies for the treatment of cancer, today announced it will be providing an update on its SIRPaFc immune checkpoint inhibitor ...</description><guid isPermaLink="false">yahoo_finance/1965585087</guid><pubDate>Thu, 14 Apr 2016 11:00:00 GMT</pubDate></item><item><title>Trillium To Present At The 2016 Annual Needham Health Care Conference</title><link>http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=128f1gr92/*http://www.publicnow.com/view/3A79086B92C5630FB5D97415A76B2E1F25EADE67</link><description>[at noodls] - Toronto, Ontario - April 12, 2016 - Trillium Therapeutics Inc. (NASDAQ:TRIL; TSX: TR) a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced ...</description><guid isPermaLink="false">yahoo_finance/2474847283</guid><pubDate>Tue, 12 Apr 2016 11:14:11 GMT</pubDate></item><item><title>Trillium to Present at the 2016 Annual Needham Health Care Conference</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-present-2016-annual-needham-110000548.html</link><description>[Marketwired] - Trillium Therapeutics Inc. a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that Dr. Niclas Stiernholm, President and Chief Executive ...</description><guid isPermaLink="false">yahoo_finance/86700797</guid><pubDate>Tue, 12 Apr 2016 11:00:00 GMT</pubDate></item><item><title>Trillium Adopts Advance Notice By-law Amendment</title><link>http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=128sl9jev/*http://www.publicnow.com/view/BBB0EA43559FC4FE6255E4171D6F226136630865</link><description>[at noodls] - Toronto, Ontario - March 23, 2016 - Trillium Therapeutics Inc. (NASDAQ:TRIL; TSX: TR) a clinical immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that ...</description><guid isPermaLink="false">yahoo_finance/918487741</guid><pubDate>Wed, 23 Mar 2016 11:32:25 GMT</pubDate></item><item><title>Trillium Adopts Advance Notice By-Law Amendment</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-adopts-advance-notice-law-110000805.html</link><description /><guid isPermaLink="false">yahoo_finance/417492809</guid><pubDate>Wed, 23 Mar 2016 11:00:00 GMT</pubDate></item><item><title>Trillium Announces a $3.4 Million Government Co-Funded Translational Research Program</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-announces-3-4-million-140000258.html</link><description /><guid isPermaLink="false">yahoo_finance/1064519886</guid><pubDate>Thu, 10 Mar 2016 14:00:00 GMT</pubDate></item><item><title>Trillium reports 4Q loss</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://sg.finance.yahoo.com/news/trillium-reports-4q-loss-232857800.html</link><description /><guid isPermaLink="false">yahoo_finance/4029719200</guid><pubDate>Wed, 09 Mar 2016 23:28:57 GMT</pubDate></item><item><title>Fluorinov Lead Programs</title><link>http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=128605gei/*http://www.publicnow.com/view/F04113FC673C81379B9AAC086DE35EC60601D53E</link><description>[at noodls] - Slide 1 The chemistry of better medicines Fluorinov Pharmaceuticals Non-Confidential Overview of Lead Programs January, 2016 This presentation may contain forward-looking statements, which reflect Fluorinov's/ ...</description><guid isPermaLink="false">yahoo_finance/610332798</guid><pubDate>Wed, 27 Jan 2016 14:07:06 GMT</pubDate></item><item><title>Q1 2016 Corporate Presentation</title><link>http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=125ro0t2t/*http://www.noodls.com/view/761D2097ED170DE21B4F13AC9E8A03C052339D0F</link><description>[at noodls] - PowerPoint Presentation Q1/2016 This presentation may contain forward-looking statements, which reflect Trillium's current expectation regarding future events. These forward-looking statements involve ...</description><guid isPermaLink="false">yahoo_finance/3384637256</guid><pubDate>Tue, 12 Jan 2016 22:25:24 GMT</pubDate></item><item><title>J.P. Morgan 34th Annual Healthcare Conference</title><link>http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=125ac2dj2/*http://www.noodls.com/view/D281DC3601AA58EC06CFD869745A025871509133</link><description>[at noodls] - PowerPoint Presentation J.P. Morgan 34th Annual Healthcare Conference January 11-14, 2016 This presentation may contain forward-looking statements, which reflect Trillium's current expectation regarding ...</description><guid isPermaLink="false">yahoo_finance/2268536007</guid><pubDate>Tue, 12 Jan 2016 21:55:03 GMT</pubDate></item><item><title>ASH 2015 Presentation</title><link>http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=1257qgv5l/*http://www.noodls.com/view/AA75ED63A0CC9C29A6EDA212AA50D2D4B3107594</link><description>[at noodls] - Slide 1 SIRP&#945;Fc, a CD47-Blocking Cancer Immunotherapeutic, Sensitizes Malignant B Cells to Macrophage-Mediated Destruction Natasja Nielsen Viller1,2, Saman Maleki Vareki2,3, Karen Dodge1, Hui Chen1, Vivian ...</description><guid isPermaLink="false">yahoo_finance/1151329907</guid><pubDate>Fri, 01 Jan 2016 06:14:08 GMT</pubDate></item></channel></rss>